Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (Mel55)
Sponsors and Collaborators
Craig L Slingluff, Jr
GlaxoSmithKline
Contacts
Kristy Scott, BS
(434) 982-6714
Alison Gaucher, BS
(434) 982-1901
Investigator
Craig L Slingluff, MD
University of Virginia
ClinicalTrials.gov Identifier
